Good News | Lister has expanded its business to be located in Hangzhou and has passed the review of the innovation and entrepreneurship project in Yuhang District.

The expansion business was established<LISTER (Hangzhou) BIOMEDICAL CO.,LTD>

The new factory is located in the Dongheng Science and Technology Innovation (Pharmaceutical) Industrial Park of Hangzhou.

Lister Medical was established in 2023 and officially moved into Hangzhou Dongheng Science and Technology Innovation (Pharmaceutical) Industrial Park in October 2025. We are a high-tech enterprise dedicated to innovative technologies for sterilization validation and monitoring of medical devices, committed to providing scientific, comprehensive and reliable sterilization process validation products and solutions for the medical, pharmaceutical and industrial fields. With the mission of "ensuring life safety", it aims to represent "Made in China" in global competition and build a medical brand with international influence.

Successfully passed the review of the third batch of innovation and entrepreneurship projects and the third batch of technology transfer projects in Yuhang District in 2025.

On November 29, 2025, the review meeting for the third batch of innovation and entrepreneurship projects and the third batch of technology transfer projects in Yuhang District in 2025 was successfully concluded. After several rounds of strict screening and expert review, LISTER (Hangzhou) BIOMEDICAL CO.,LTD stood out and successfully passed the review, officially being included in the list of key supported innovation and entrepreneurship projects in Yuhang District. This marks that Liszt has been highly recognized by the government for its outstanding technological innovation capabilities and clear industrialization prospects.

This review focused on strategic emerging industries such as artificial intelligence, biomedicine, intelligent manufacturing, and low-altitude economy, attracting many high-quality projects with core technologies and industrialization potential to participate. The successful selection of an enterprise is not only a concentrated reflection of its own technological strength, team level and development prospects, but also fully demonstrates the solid achievements of the park in industrial cultivation, enterprise services and the construction of an innovation ecosystem.

Lister Medical is a benchmark of "Made in China" in the field of sterilization monitoring.

1. The core technological advantages are remarkable

The company focuses on the independent research and development and production of biological indicators and chemical indicators, and has established a full-chain technical system covering strain selection and breeding, chemical formula, and intelligent reading and judgment. The company's flagship rapid biological indicator can provide precise sterilization results within 10 minutes, featuring both high accuracy and high efficiency, making it the "ultimate judge" in the sterilization verification field.

2. Leading innovation capability in the industry

The company takes the integration of biological and chemical technologies as its core and continuously promotes product iteration and scenario expansion. The enzyme indicator under development has shortened the detection time to 6 seconds, and forward-looking products such as complex instrument process challenge devices and penetrating biological indicators have been laid out, aiming to break through the technical barriers of high-end sterilization monitoring. The company has developed a complete product matrix covering various sterilization methods such as steam, ethylene oxide, and hydrogen peroxide, which can be adapted to a wide range of demanding application scenarios including hospitals, pharmaceutical companies, and laboratories.

3. The industrialization process has been steadily advancing

The company has established an annual production capacity of one million biological indicators and has obtained international certifications such as CE and ISO13485. Its products are sold to many countries and regions including Australia, Southeast Asia and Latin America. The sales volume is expected to reach 8 million yuan in 2024 and exceed 20 million yuan in 2025. The company has completed the full integration of Anhui Liszt and is now focusing on transforming Hangzhou into a group headquarters integrating R&D, production and sales. It plans to complete the comprehensive upgrade of production capacity and platform by 2026.

Lister is steadily growing into an innovation benchmark in the domestic sterilization monitoring field with its solid technological accumulation, clear product path and rapid industrialization capabilities, continuously injecting strong impetus into promoting the independent control of China's medical device aseptic guarantee system and participating in global competition.